Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
101.66
+0.98 (0.97%)
At close: Jul 20, 2026, 4:00 PM EDT
101.74
+0.08 (0.08%)
After-hours: Jul 20, 2026, 7:15 PM EDT
Abbott Laboratories Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Abbott Laboratories stock has a consensus rating of "Buy" and an average price target of $118.54. The average 1-year stock price forecast is 16.60% higher than the current stock price, while the lowest is $92 (-9.50%) and the highest is $135 (+32.80%).
Price Target: $118.54 (+16.60%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Abbott Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 16 | 16 | 16 | 17 | 16 |
| Buy | 6 | 6 | 5 | 4 | 4 | 4 |
| Hold | 7 | 7 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 28 | 27 | 28 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Jefferies No rating | Jefferies | Buy Reiterates $135 | Buy | Reiterates | $135 | +32.80% | Jul 17, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $115 → $118 | Buy | Reiterates | $115 → $118 | +16.07% | Jul 17, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $130 | Buy | Reiterates | $130 | +27.88% | Jul 17, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $110 → $120 | Buy | Maintains | $110 → $120 | +18.04% | Jul 17, 2026 |
| Citi | Citi | Buy Maintains $108 → $112 | Buy | Maintains | $108 → $112 | +10.17% | Jul 17, 2026 |
Financial Forecast
Revenue This Year
50.31B
from 44.33B
Increased by 13.50%
Revenue Next Year
54.70B
from 50.31B
Increased by 8.72%
EPS This Year
5.51
from 5.15
Increased by 7.01%
EPS Next Year
6.07
from 5.51
Increased by 10.08%
EPS and Forward PE are based on non-GAAP adjusted numbers.